真實譯文展示（如有保密內(nèi)容均以XX代替）
Real translation show (All confidential contents are replaced with XX)
In its World Economic Outlook October 2021, the International Monetary Fund noted the various impediments to an economic rebound in the second half of 2021 described above. But it has revised down its forecast for global economic growth in 2021 by just 10 basis points to 5.9%. More tellingly, it has maintained its forecast for global growth of 4.9% in 2022, in an apparent show of confidence that the headwinds of recent months will not linger long enough or substantially enough to hurt economic prospects next year.
在國際貨幣基金組織2021年10月發(fā)布的《世界經(jīng)濟展望》中，提到了上文所述的2021年下半年經(jīng)濟反彈所面臨的諸多障礙。但國際貨幣基金組織僅將2021年的全球經(jīng)濟增長預測向下修正了10個基點，調(diào)整為5.9%。更重要的是，國際貨幣基金組織維持了2022年全球經(jīng)濟增長4.9%的預測，這表明該組織并不認為最近幾個月的挑戰(zhàn)會持續(xù)太長時間，其嚴重程度不足以影響2022年的經(jīng)濟前景。
Our view remains cautiously upbeat as well. The principal reason for this optimism is our baseline scenario for the global pandemic. There are several reasons why the headwinds to growth induced by the pandemic are likely to dissipate:
我們同樣堅持謹慎樂觀的態(tài)度。我們之所以持這種樂觀的態(tài)度，主要原因在于全球疫情基線情景。有多個原因可以解釋疫情對經(jīng)濟增長造成的障礙可能逐步消失，例如：
The rollout of vaccines is improving, even in countries which were initially slow to vaccinate. As we write this, India is vaccinating its population at a rate of roughly 8 million every day. Malaysia similarly overcame teething problems and has now fully vaccinated close to 90% of its adult population, an achievement on par with most developed countries.
疫苗普及正在加速，即使那些最初接種緩慢的國家也是如此。正如我們在之前的報告中所提到的，印度每天約800萬人接種疫苗。馬來西亞同樣克服了初期的問題，目前接近90%的成年人口已經(jīng)完成疫苗接種，這一成就與大部分發(fā)達國家相比也毫不遜色。
Large populous countries such as India and Indonesia are experiencing precipitous declines in COVID-19infections, even when vaccination rates are not high, suggesting a good degree of resistance within the population.
印度、印尼等人口眾多的國家，在疫苗接種率不高的情況下，新冠新增病例數(shù)依舊能急劇下降，表明人口對新冠的抵抗力在增強。
Treatment regimens for the illnesses resulting from COVID-19 are also improving. Better clinical management and a wider range of medications have helped to bring down the fatality rate, while also reducing the chances that an infected patient’s condition turns critical. The imminent introduction of new drugs such as Merck’s antiviral drug, Molnupiravir, which can reduce the risk of hospitalization and death in at-risk patients by 50% will go further in making the disease a less terrifying one and one which people can learn to live with.
新冠肺炎治療藥物也在逐漸完善。良好的臨床管理和更多藥物的出現(xiàn)，幫助降低了新冠肺炎患者的致死率以及病情惡化的幾率。默克制藥的抗病毒藥物Molnupiravir可將高?；颊咦≡褐委熀退劳龅娘L險降低50%，這些新藥上市將進一步降低新冠肺炎的嚴重性，使人們能夠逐步學會與病毒共存。